Important Safety Information Prescribing Information Patient Site

Cost and Savings

Cost and savings for your patients

Model is for illustrative purposes only.

Copay Assistance Program

Patients with commercial insurance who meet the eligibility requirements can save on their out-of-pocket expenses with the support of the Copay Assistance Program.*

The copay amount each patient pays your practice depends on:

  • Whether their insurance covers YCANTH
  • The type of commercial insurance they have
  • Whether or not they have met their deductible

Offices using Y-Access® Support Solutions or Verrica's Specialty Pharmacy Network can have their patient automatically enrolled into the Copay Assistance Program.

Most patients pay as little as:

$25

If deductible has not been met, or insurance does not cover YCANTH, patient pays practice no more than $75 per applicator.

Remind patients that flexible spending accounts (FSA) or health savings accounts (HSA) can help cover copay expenses. Healthcare expense accounts can help offset qualified out-of-pocket expenses. Encourage patients to check with their program provider. Additional terms and conditions may apply.

*
Copay Assistance Program is solely for patients' charges incurred in the use of YCANTH (cantharidin) topical solution and does not include any other related charges. For all qualified patients, Verrica is responsible for all YCANTH product costs under the Program amount and excluding the copay requirement. Your insurance provider can provide the most accurate explanation of all charges. Approval to the Program is not guaranteed. Program has an annual maximum benefit of $2,605 or 4 treatments for YCANTH, whichever occurs first. Until the patient reaches the maximum Program benefit, providing healthcare professionals may not charge the patient more than the applicable Program allowance. Patient will bear financial responsibility for all costs not covered by commercial insurance exceeding maximum benefit for YCANTH. THIS IS NOT INSURANCE. Not valid for prescriptions paid, in whole or in part, by Medicaid, Medicare, VA, DOD, TRICARE®, or other federal or state programs including any state pharmaceutical assistance programs. This Program is not valid where prohibited by law, taxed or restricted. Verrica reserves the right to rescind, revoke, terminate, or amend this offer, eligibility, and terms of use at any time without notice. Additional terms and conditions may apply.

TRICARE® is a registered trademark of the Department of Defense (DOD), DHA.

Visit Y‑AccessSupport.com to learn about the eligibility requirements and enroll your patients in the Copay Assistance Program

YCANTH list price

The list price, or Wholesale Acquisition Cost (WAC), is $685 per applicator of YCANTH as of July 2023. The WAC may not reflect the price paid by patients.

YCANTH Box

Photo is for illustrative purposes only.

Pricing Table

YCANTH is not available through retail pharmacies and can only be ordered from our exclusive distributor and our Specialty Pharmacy Network. Any third-party sites reporting cost or availability of YCANTH via retail pharmacies are not accurate and are not authorized by Verrica Pharmaceuticals.

Call 1-877-VERRICA (1-877-837-7422) to find out how much YCANTH may cost for your patients

YCANTH has strong insurance coverage across commercial and Medicaid plans

  • 90% coverage across the top commercial plans1†
  • Covered by many state Medicaid and managed Medicaid plans

†Based a review of the top 50 health plans in the United States.1

Photo is illustrative and not representative of all patients.

Questions about insurance or coverage for your patients?

Contact a Field Reimbursement Manager (FRM) at marketaccess@verrica.com or call 1-877-VERRICA (1-877-837-7422)

Y-Access Support Solutions

Y-Access Support Solutions provides white glove service that can help your patients save on costs, including:

  • Automated copay enrollment for eligible patients
  • Assistance with benefit investigations and prior authorizations
  • Details about prior authorization requirements and appeals
  • Billing and coding support from FRMs, including claim submissions and resubmissions, if needed

Model is for illustrative purposes only.

Y-Access Support Solutions is here to help. To register your practice or connect with an FRM:

Y-AccessSupport.com

1-855-YCANTHS (1-855-922-6847)

For more helpful resources and additional information, visit YCANTHPro.com/office-resources.

You are about to leave the YCANTHPro.com website by opening a new webpage. The site you are linking to is not controlled by Verrica Pharmaceuticals and we are not responsible for the content presented on that site.

Thank you for visiting YCANTHPro.com.

Leave site

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: None.

WARNINGS AND PRECAUTIONS:

  • YCANTH is for topical use only. YCANTH is not for oral, mucosal, or ophthalmic use. Life threatening or fatal toxicities can occur if YCANTH is administered orally. Avoid contact with the treatment area, including oral contact, after treatment. Ocular toxicity can occur if YCANTH comes in contact with eyes. If YCANTH gets in eyes, flush eyes with water for at least 15 minutes.

INDICATION

YCANTH (cantharidin) topical solution, 0.7% is indicated for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: None.

WARNINGS AND PRECAUTIONS:

  • YCANTH is for topical use only. YCANTH is not for oral, mucosal, or ophthalmic use. Life threatening or fatal toxicities can occur if YCANTH is administered orally. Avoid contact with the treatment area, including oral contact, after treatment. Ocular toxicity can occur if YCANTH comes in contact with eyes. If YCANTH gets in eyes, flush eyes with water for at least 15 minutes.
  • Local Skin Reactions: Reactions at the application site may occur, including vesiculation, pruritus, pain, discoloration, and erythema. Avoid application near eyes and mucosal tissue, and to healthy skin. If YCANTH contacts any unintended surface, or healthy skin, immediately remove. If severe local skin reactions occur, remove prior to the recommended 24 hours after treatment.
  • YCANTH is flammable, even after drying. Avoid fire, flame or smoking near lesion(s) during treatment and after application until removed.

ADVERSE REACTIONS:

The most common (incidence ≥1%) reactions are the following local skin reactions at the application site: vesiculation, pain, pruritus, scabbing, erythema, discoloration, application site dryness, edema, and erosion. Local skin reactions at the application site were observed in 97% of subjects treated with YCANTH during clinical trials. These local skin reactions are expected and related to the anticipated blistering response of the skin to cantharidin.

DRUG INTERACTIONS:

No studies evaluating the drug interaction potential of cantharidin have been conducted.

USE IN SPECIFIC POPULATIONS:

Pregnancy: There are no available data with use of YCANTH in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Given that systemic exposure to cantharidin following topical administration is low, maternal use is not expected to result in fetal exposure to the drug.

Lactation: Avoid application of YCANTH topical solution to areas with increased risk for potential ingestion by or ocular exposure to the breastfeeding child.

OVERDOSAGE:

Oral ingestion of cantharidin has resulted in renal failure, blistering and severe damage to the gastrointestinal tract, coagulopathy, seizures, and flaccid paralysis.

Please see full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact Verrica Pharmaceuticals Inc. at 1-877-VERRICA (1-877-837-7422), or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Local skin reactions are expected and should be reported if they are severe.

Reference: 1. Data on file. Verrica Pharmaceuticals Inc., 2024.

DHA=Defense Health Agency; DOD=Department of Defense; NDC=National Drug Code; VA=Veterans Affairs.